Q3

Indo Us Bio-Tech Ltd

INDOUSFY2621 Jan 2026

Revenue-26.1%

Net Profit-13.2%

OPM18.20%

P&L

Quarterly Standalone

Revenue

-26.1%22.80

Expenditure

-28.1%19.64

Net Profit

-13.2%3.00

NPM 13.14%+17.5%EPS ₹1.49-13.4%

vs Q2 FY26

Informational and educational content only. Not investment advice.